The effect of inhaled hypertonic saline (HS) on mucus-ciliar clearance in Cystic Fibrosis (CF) patients is well known. Several studies evaluated its efficacy on lung function and number of exacerbations. In our study we evaluated if its use may have any positive effect on nutritional status in CF patients. Methods and Patients: In CF patients receiving HS 7% (5 ml twice/day) for at least 18 months, a retrospective evaluation of FVC, FEV 1 and BMI pre-and during treatment period (T0, and every 6 mo) was performed. 14 CF patients (8 males) aged 7−25 ys (mean age 17 y2 mo) who received HS for 18−36 months consecutively (mean duration of treatment 32 mo) entered the study. Chronic Pseudomonas aeruginosa infection was present in 9 patients, 1 also presented ABPA, 3 patients have CFRD. Four out of 14 received nutritional supplementation (1 enteral, 3 oral) during the study period. Results: At starting HS only 2/14 patients had a FEV 1 lower than 70% predicted. During treatment FEV 1 and FVC remained stable or showed a slight improvement in 11/14 patients. As regard nutritional status a good improvement was noted in mean BMI: BMI equal to 17.84 at start, showed a progressive increasing to 19.45 after 36 months in the whole studied cases. The increase of mean BMI from 18.2 to 20 was observed in the patients (10) not receiving nutritional supplementation. Conclusions: Long-term HS has a positive effect on nutritional status in adolescent patients with mild-moderate CF lung disease. Evaluation of growth and nutritional status in a larger number of patients receiving long-term HS is needed to confirm this preliminary observation.
Introduction: Lung transplantation (LTx) is a widely accepted treatment for end stage cystic fibrosis (CF). The prevalence of secondary pulmonary hypertension (PH) in CF patients is estimated with ultrasound to be 21−49%. But the gold standard, heart catheterization, is used in few studies because of the invasive nature. The existence of PH increases the perioperative risk. Therefore, we measured mean pulmonary artery pressure by right heart catheterization, in CF patients screened for LTx. Methods and Materials: CF patients evaluated for LTx between 2001 and 2008 were included. We excluded patients with incomplete or conflicting data. Right heart catheterization was performed according to our protocol. PH was defined as mean pulmonary artery pressure greater than 25 mmHg at rest with a pulmonary capillary wedge pressure of 15 mmHg or less. The forced expiratory volume in one second was determined at moment of catheterization. Results: 73 CF patients were screened for LTx and 68 were included (of whom 93% accepted for LTx). Median age was 31 (range 16−57) years at moment of screening. During the study period, 35 patients were transplanted (56%) after a median waiting time of 10 months (range 0−49). 16 CF patients (24%) were diagnosed with PH by heart catheterization. No significant differences were observed between the groups with or without PH regarding to age, gender and number of enlisted patients. Lung function was significantly lower in the group with PH (p = 0.003). No correlation between lung function and mean pulmonary artery pressure was found (p = 0.09). Conclusions: This study demonstrated a prevalence of 24% for pulmonary hypertension in CF patients screened for LTx. In the last decade, lung transplantation (LT) has become an "ordinary" option in CF patients with severe impairment of lung function. The spirometry is the easiest and less expensive functional test utilized to follow-up these patients after LT. Objective: To analyze the trend of spirometry after LT. Methods: In more than 12 years we evaluated 60 CF patients (34 M, age 25.8±7.5 yrs) who underwent double-lung transplantation for severe respiratory failure. Forced expiratory volumes have been detected one month after LT, every 3 months during the first year and every 6 months after the first year. We analyzed mainly the FEV1 in form of percent of predicted values. Results: After LT, all but three patients showed a rising trend in FEV1 that reached a peak after 16.3±11.5SD months (rarely this phase was longer than 30 months). The mean increase in FEV1 was 37.8±17.8DS% (differences calculated from the values observed at the first spirometry after LT). During our observation 21 patients died after a mean period of 53±38.8SD months. In all but five of the deceased patients, a sudden reduction in FEV1 has been observed in the last 6 months. In alive patients, we observed three different FEV1 trends after the peak: 22 patients remained stable around the peak values; 12 patients had a descending trend with a rate of reduction of −4.5±2.4%/yr; 5 patients showed a stable phase followed by a sudden reduction (−39.8±10.5%) and a subsequent stabilization.
Conclusions:
The spirometry is an useful tool that give important information on the lung health after lung transplantation, however it is not able to predict the sudden reduction in lung function that is observed in deceased patients.
